propan-2-yl (2R)-2-[[[(2S,3S,4R,5R)-5-(2-amino-6-ethoxypurin-9-yl)-2-fluoro-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: propan-2-yl (2R)-2-[[[(2S,3S,4R,5R)-5-(2-amino-6-ethoxypurin-9-yl)-2-fluoro-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
• 化学式: C₂₄H₃₂FN₆O₉P
• 分子量: 598.5
• InChiKey: IBPPCLUVCZJOCT-XTEGDZSUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  41
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  202
• 氢给体数：
  4
• 氢受体数：
  15

文献信息

• D-AMINO ACID COMPOUNDS FOR LIVER DISEASE
  申请人：Idenix Pharmaceuticals LLC

  公开号：US20160002281A1

  公开（公告）日：2016-01-07

  Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

  本文提供了用于治疗肝脏疾病和病状（包括HCV感染）的化合物、组合物和方法。在某些实施例中，披露了核苷衍生物的化合物和组合物，可以单独或与其他抗病毒药物联合使用。
• [EN] D-AMINO ACID COMPOUNDS FOR LIVER DISEASE<br/>[FR] COMPOSÉS D'ACIDE D-AMINÉ CONTRE LES MALADIES HÉPATIQUES
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2013177219A1

  公开（公告）日：2013-11-28

  Provided herein are compounds comprising a D-amino acid, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

  本文提供了包含D-氨基酸的化合物、用于治疗肝脏疾病和状况（包括HCV感染）的组合物和方法。在某些实施例中，披露了核苷衍生物的化合物和组合物，可以单独或与其他抗病毒剂联合使用。
• [EN] 4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV<br/>[FR] 4'-FLUORO-NUCLÉOSIDES POUR LE TRAITEMENT DU VHC
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2014099941A1

  公开（公告）日：2014-06-26

  Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula (1501): or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, RA, RB, RC, L, M and Z are as described herein.